REFERENCES
- Rosenthal DS, Braunwald E. Hematologic disorders and heart disease. In: Braunwald E, ed., Heart disease. A textbook of cardiovascular medicine. Philadelphia: WB Saunders, 1980: 1784–7.
- Posner MR, Cohen GI, Skarin AT. Pericardial disease in patients with cancer. Am J Med 1981; 71: 407–13.
- Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer 1995; 76: 1377–87.
- Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Lorell BH, Simons M. Pericardial effusion in patients with cancer: out-come with contemporary management strategies. Heart 1996; 75: 67–71.
- Winters WL, Cortes FM. Pericardial disease. In: Conn HL, Horwitz O. Cardiac and vascular disease. Philadelphia: Lea and Febinger, 1971: 1328-87.
- Vaitkus PT, Herrmann HC, LeWinter MM. Treatment of malignant pericardial effuion. JAMA 1994; 272: 59–64.
- Kohnoe S, Maehara Y, Takahashi I, et al. Intrapericardial mitomycin-C for the management of malignant pericardial effusion secondary to gastric cancer. Case report and review. Chemotherapy 1994; 40: 57–60.
- Tomkowski WZ, Filipecki S. Intrapericardial cisplatin for the management of patients with large malignant pericardial effuion in the course of the lung cancer. Lung Cancer 1997; 16: 215–22.
- Aasebø U, Norum J, Sager G, Sim-dal L. Intrapleurally instilled mitoxantrone in metastatic pleural effuions: a phase II study. J Chemother 1997; 9: 106–11.
- Mahrer EA, Shepherd FA, Todd TJR. Pericardial scle-rosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996; 112: 637–43.
- Lerner-Tung MB, Chang AYC, Ong LS, Kreiser D. Pharmacokinetics of intrapericardial administration of 5-fluorouracil. Cancer Chemother Pharmacol 1997; 40: 318–20.
- Kuhn K, Purea H, Selbach J, Westerhausen M. Treatment with locally applied mitoxantrone. Acta Med Austriaca 1989; 16: 87–90.